Min Li to Carcinoma, Pancreatic Ductal
This is a "connection" page, showing publications Min Li has written about Carcinoma, Pancreatic Ductal.
Connection Strength
3.280
-
Shared HLA-Bound Neoepitopes Are New Targets for Pancreatic Cancer Immunotherapy. Clin Cancer Res. 2025 May 15; 31(10):1821-1823.
Score: 0.838
-
Patient-Derived Organoid Pharmacotyping Guides Precision Medicine for Pancreatic Cancer. Clin Cancer Res. 2022 08 02; 28(15):3176-3178.
Score: 0.691
-
A Novel Translational Activation of HIF1a Promotes Pancreatic Cancer Growth Through Glycolytic Reprogramming. Gastroenterology. 2022 04; 162(4):1040-1042.
Score: 0.667
-
Interplay of Tumor Microenvironment Factors and Cancer Stem Cell Enrichment in Pancreatic Ductal Adenocarcinoma. Gastroenterology. 2021 12; 161(6):1800-1802.
Score: 0.650
-
An integrated model of N6-methyladenosine regulators to predict tumor aggressiveness and immune evasion in pancreatic cancer. EBioMedicine. 2021 Mar; 65:103271.
Score: 0.157
-
An allosteric PGAM1 inhibitor effectively suppresses pancreatic ductal adenocarcinoma. Proc Natl Acad Sci U S A. 2019 11 12; 116(46):23264-23273.
Score: 0.143
-
Discriminating patients with early-stage pancreatic cancer or chronic pancreatitis using serum electrospray mass profiling. Cancer Lett. 2015 Apr 10; 359(2):314-24.
Score: 0.103
-
PIN1 Maintains Redox Balance via the c-Myc/NRF2 Axis to Counteract Kras-Induced Mitochondrial Respiratory Injury in Pancreatic Cancer Cells. Cancer Res. 2019 01 01; 79(1):133-145.
Score: 0.033